0.51 USD
↘ 0.00 (0.90%)AT CLOSE (03:59 PM EDT)
Jasper Therapeutics, Inc. Common Stock
JSPRNASDAQ • USD
0.50
↘ 0.00 (0.28%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
0.50
↘ 0.00 (0.28%)
Market: CLOSED
JSPR is currently priced at $0.50. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation front, JSPR trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Oct 26, 2026.
Open?$0.51
High?$0.52
Low?$0.50
Prev. Close?$0.51
Volume?396.7K
Avg. Volume?367.9K
VWAP?$0.51
Rel. Volume?1.08x
Bid / Ask
Bid?$0.48 × 1.3K
Ask?$0.54 × 500
Spread?$0.06
Midpoint?$0.51
Valuation & Ratios
Market Cap?17.0M
Shares Out?33.3M
Float?28.6M
Float %?86.0%
P/E Ratio?N/A
P/B Ratio?12.01
EPS?-$0.95
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Employees
22
Market Cap
17.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2021-09-27
Address
2200 BRIDGE PKWY SUITE #102
REDWOOD CITY, CA 94065
Phone: (650) 549-1400
REDWOOD CITY, CA 94065
Phone: (650) 549-1400
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?77
Short Sent.?19
Piotroski F-Score?0/9Weak
Altman Z-Score?-52.10Distress
Confidence?44%Low
Short InterestSqueeze Risk
Short % of Float?22.62%Squeeze Risk
Short Interest?6.5M
Days to Cover?18.5
Free Float28.6M
Avg Daily Volume349.4K
Settlement Date2026-10-15
Financial Health
Current Ratio?1.47Adequate
Quick Ratio?1.47Adequate
Cash Ratio?0.93Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?12.01HIGH▾
Peers100
S&P16
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.2CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-2,248.5%WEAK▾
S&P3
ROA?-269.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-60333000
Enterprise Value?$9.7M
Fundamentals ratios updated end of day